Private financing · Diligence design

The biotech fundraising
data room checklist

A financing room is judged on one thing: whether an investor can get from interest to conviction without waiting on you. That depends less on how much you upload than on what you open, to whom, and in what order

Direct answer

A biotech fundraising data room holds six groups of evidence: corporate records and the cap table, the financial model and runway, the program evidence behind the next clinical inflection, the intellectual property position, manufacturing and supply at the depth the round requires, and team, governance and market. The organizing question is not what exists but what an investor must verify before pricing the round. Staged disclosure decides the rest: narrative and headline financials open early, the detailed record opens on mutual interest, and the most sensitive material waits for confirmatory diligence after a term sheet.

Evidence groups06

Disclosure stages04

Reader lanes04

Editorial modelSource-led

01 · The checklist

Six groups an investor has to clear

A financing room is not a smaller version of an IPO room. It is organized around the decision an investor is making: whether this capital reaches a value event before the money runs out

Corporate records and cap table

The cheapest round to diligence is the one where ownership arithmetic is already settled and documented

Formation documents, charter, bylaws and the current stockholder and board consent record
Fully diluted cap table including options granted and reserved, warrants and convertible instruments
Conversion mechanics for outstanding notes and safes, with the trigger terms written out
Economic terms of existing preferred stock, including liquidation preference, participation and anti-dilution provisions
Equity plan documents, grant agreements and the most recent independent valuation
Prior financing documents so the terms an investor models can be confirmed against the agreements

Owner · CFO and general counsel

Financial model and runway

Runway is the number every investor recalculates themselves, so the room should make their version easy to build

Historical financial statements and the current monthly burn broken down by function
Cash position as of a stated date, with the reconciliation to the last closed month
Operating model with the assumptions separated from the outputs and marked as assumptions
Use of proceeds presented as a bridge from cash today to the milestone the round is meant to reach
A downside case showing what the company does if the next milestone slips by two quarters
Committed spend, contract research obligations and any minimum purchase commitments

Owner · CFO

The next clinical inflection

The round is priced on the next inflection, not on the whole pipeline. That evidence deserves its own depth

A written definition of the inflection: the study, the readout, the date and what result counts as success
Protocols and amendments, with the reason recorded for each change
Study status, enrollment progress and site activation against the plan
Safety reporting record and any events that changed the conduct of the study
Analysis plan governing any interim or blinded analysis that has been shared
Preclinical package supporting the dose, schedule and population under study

Owner · Chief medical officer and chief scientific officer

Intellectual property position

Investors are underwriting exclusivity as much as data, and exclusivity questions do not resolve quickly under time pressure

Patent families with status, jurisdictions and expected term for the asset being financed
Assignment chain from every named inventor, including former employers and academic institutions
In-bound licence agreements with the diligence, milestone and royalty obligations they carry
Any government funding interests or institutional rights attached to the underlying research
Trade secret and know-how practices where protection does not rest on patents
Prosecution history and pending office actions for the core families

Owner · General counsel and patent counsel

Manufacturing and supply

Early rounds do not need a validated process. They do need evidence that the material used in the data can be made again

Process description at the stage of development the round supports
Batch record for the material used in the studies being presented
Analytical methods and specifications in use, and their current qualification status
Contract manufacturer agreements, capacity commitments and technology transfer status
Stability data supporting the storage and shelf-life assumptions in the plan
Supply risks that would delay the next study, with the mitigation already in motion

Owner · Technical operations

Team, governance and market

The last group is where a strong round is confirmed rather than won, but a weak one is where it stalls

Organization chart, hiring plan against the use of proceeds and key-person exposure
Employment, consulting and advisory agreements, with invention assignment confirmed
Board composition, observer rights and existing investor information rights
Indication and target population reasoning, with the sources separated from the estimates
Competitive landscape including programs in the same mechanism or population
Regulatory strategy for the path beyond the round, at the level of detail already supported

Owner · CEO

02 · Staged disclosure

Open the room in the order the decision is made

Opening everything at once is slower, not faster. It buries the evidence that drives the decision and exposes the most sensitive material to parties who never reach a term sheet

StepWhat opensWho readsWhat waits

First conversationNarrative, program map, headline financials, teamPartner or principal screening the opportunityUnderlying study data and all contracts

Mutual interestProtocols, study status, cap table, model, patent listDeal team and scientific advisersUnredacted agreements and participant-level data

After the term sheetFull contract set, batch and analytical records, correspondenceConfirmatory diligence, counsel, technical reviewersMaterial outside the agreed diligence scope

Signing and closingDisclosure schedules, consents, closing deliverablesCounsel on both sides and the boardNothing relevant; gaps become schedule exceptions

03 · Reader lanes

Four readers, four different rooms

The same underlying record serves all four. Duplicating it per audience is how versions drift apart and how the wrong file reaches the wrong reader

Decision

Lead investor

Reads for the investment case: whether the round reaches a defined inflection, what the ownership and terms look like afterwards, and what the downside case costs if the timeline slips

Science

Scientific diligence adviser

Reads for reproducibility and provenance: whether the data supports the claimed effect, whether the analysis was pre-specified, and whether the preclinical package justifies the current design

Verification

Fund finance, operations and counsel

Reads for confirmation: capitalization arithmetic, existing rights and preferences, contract obligations, employment and invention assignment, and anything that becomes a closing condition

Continuity

Existing investors and board

Read for consistency with what was represented at the last round, for the effect of new terms on existing holders, and for whether the operating plan still matches the capital being raised

04 · Investor questions

What the room is actually asked

What exactly is the next inflection

Which study, which readout, on what date, and what specific result would make the next round easier rather than harder to raise

Does the runway clear that inflection

How many months of cash remain at current burn, how much margin sits beyond the expected readout date, and what the plan is if the date moves

What does the waterfall look like

Under several exit values, how proceeds distribute across existing preferences, the new round and common holders, and which agreements set those terms

Where does the money actually go

How use of proceeds maps to headcount, clinical spend and manufacturing, and which line items are committed rather than planned

Who can make this besides you

What the patent position actually covers, what obligations came with in-bound licences, and whether the assignment chain has a gap

Can you make the material again

Whether the batch behind the presented data is documented, whether the process can be repeated at the next scale, and who holds that capability

05 · Update triggers

What forces the room to be refreshed

Month-end close

Cash, burn and runway are dated figures. A room carrying last quarter's cash position invites a correction at the worst moment

Any equity event

A grant, an exercise, a note conversion or a valuation refresh changes the cap table and every ownership calculation built on it

Study milestones

Enrollment completion, a protocol amendment, a safety event or a data cut changes both the inflection narrative and the evidence behind it

Intellectual property movement

A grant, rejection, new filing or licence amendment changes the exclusivity picture an investor is underwriting

Plan changes

A change in the operating plan, hiring schedule or manufacturing route makes the use of proceeds stale before the round closes

Editorial boundary This guide describes financing evidence, not software suitability. See the data-room selection guide for documented provider use cases and disclosure of this site's commercial interest

06 · Questions and answers

Common questions about fundraising rooms

What goes in a biotech fundraising data room?

Six groups: corporate records and the cap table, the financial model and runway, the program evidence behind the next clinical inflection, the intellectual property position, manufacturing and supply at the depth the round requires, and team, governance and market. The organizing question is not what exists but what an investor must verify before pricing the round, and in what order they are allowed to see it.

What does a Phase 2 biotech data room need that a seed round does not?

A Phase 2 round is priced on human data, so the room must support it. That means final protocols and amendments with the reasons for each change, the safety reporting record, blinded or interim analyses with the analysis plan that governed them, regulatory correspondence covering the development path, and manufacturing evidence sufficient to show the material used in the trial can be made again. A seed round is usually priced on mechanism, intellectual property and preclinical reproducibility instead.

Should everything be open in the data room from the first investor meeting?

No. Staged disclosure protects both sides and speeds the process up. Open the narrative, market position and headline financials early; open the detailed clinical, manufacturing and contract record once there is mutual interest; and reserve the most sensitive material, such as unredacted third-party agreements and individual participant data, for confirmatory diligence after a term sheet. Sequencing the room is a diligence design decision, not an administrative one.

How should use of proceeds be presented to investors?

Present it as a bridge rather than a pie chart. Show the current cash position, the monthly burn by function, the specific milestone the round is intended to reach, the date that milestone is expected, and the cash remaining after it. Investors are testing whether the raise buys a real inflection with margin for delay, so the allocation matters less than the link between spending and the next value event.

What cap table detail do investors expect before a term sheet?

A current fully diluted capitalization including options granted and reserved, warrants, convertible instruments and their conversion mechanics, plus the economic terms attached to existing preferred stock. Investors model the waterfall under several exit values, so the underlying agreements have to be available to confirm the terms rather than summarized in a spreadsheet alone.

07 · Primary sources

Public records behind private rounds

Private financings leave a public trail and rely on public evidence. These are the official systems that carry it

506

Private offering exemptions

The exemption most venture financings rely on, the conditions attached to it and the notice filing that follows a closing

SEC guidance on Rule 506(b) ↗

FORM

Notice filings

The SEC form set, including the notice of an exempt offering that becomes a public record after a private round closes

SEC forms index ↗

CTG

Trial registration duties

Which studies must be registered, what results information is required and on what timetable, which sets what an investor can already see

ClinicalTrials.gov reporting requirements ↗

API

Study records

Programmatic access to study phase, status, enrollment, endpoints and sponsors for your programs and for competing ones

ClinicalTrials.gov API ↗

312

Investigational drug rules

The regulations governing investigational applications, protocol amendments and safety reporting that produce much of the clinical record

21 CFR Part 312 ↗

EDGAR

Comparable disclosure

Filings from companies that later went public, showing how the evidence assembled in private rounds is eventually described in public

EDGAR APIs ↗